Although RNA therapeutics targeting cancer associated RNA editing have not yet been introduced into the clinic, the chemically modified antisense oligonucleotides (ASOs)-mediated inhibition of AZIN1 editing effectively suppresses tumor incidence and growth, suggesting that many cancer patients with high editing level of AZIN1, may benefit from the AZIN1-targeting and ASO-based therapeutics [105], which is being developed as a novel and promising class of drug. This evidence concerns the gene AZIN1 and cancer.